Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy
January 22, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process
January 19, 2015 15:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Jan. 19, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations
January 09, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law
January 08, 2015 17:14 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers
January 07, 2015 13:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference
January 07, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy
January 06, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
December 30, 2014 08:30 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma
December 22, 2014 12:40 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Added to the NASDAQ Biotechnology Index
December 16, 2014 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE),a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...